Medical Advisory Council
The Medical Advisory Council assists the board by reviewing FD Foundation publications and helping establish research goals. This diverse advisory body includes doctors and researchers who are the experts from around the world for these rare diseases.
Alison Boyce, MD (Chair) is a pediatric endocrinologist and physician scientist in the Section on Skeletal Disorders and Mineral Homeostasis, National Institute of Dental and Craniofacial Research, National Institutes of Health (NIH). After completing undergraduate studies at the University of Virginia, she received medical and general pediatrics training at Eastern Virginia Medical School, followed by an endocrinology fellowship at the NIH. She holds a faculty appointment at Children’s National Health System, and is active in the joint NIH and Children’s National Health System’s Pediatric Fellowship training program, as well as the Children’s National Bone Health Program. Dr. Boyce’s research focuses on rare disorders of bone and mineral metabolism, including fibrous dysplasia/McCune-Albright syndrome, disorders of fibroblast growth factor-23, and hypoparathyroidism. As chair of the Medical Advisory Council, Dr. Boyce participates in board meetings in a nonvoting capacity.
Michael T. Collins, MD is an endocrinologist whose area of specialty is metabolic bone diseases and mineral metabolism. He is the Chief of the Skeletal Clinical Studies Unit of Craniofacial and Skeletal Diseases Branch at the NIH in Bethesda, MD. The primary focus of his research is polyostotic Fibrous Dysplasia (PFD) and the McCune-Albright syndrome (MAS). He is the principal investigator on several clinical studies of patients with PFD/MAS, and is a globally recognized expert on FD/MAS. Dr. Collins served as Chair of the Medical Advisory Council from 2004-2018, and continues to play an important role in advising the Fibrous Dysplasia Foundation.
Daniel Handel, MD holds board certifications in Family Practice and Hospice and Palliative Medicine. Dr. Handel is the founding Chief of Palliative Medicine at Denver Health, providing both inpatient and outpatient services through an interdisciplinary team serving patients with advanced illness since 2013, and previously held a senior clinical staff appointment at the National Institutes of Health for twelve years where he founded and led the NIH Palliative and Hospice Medicine fellowship. With special interests in pharmacological and mind/body pain strategies, Dr. Handel has presented internationally and has authored books and other thirty book chapters and journal articles on pain management, palliative care medicine, complementary medicine, hypnosis, and mind/body medicine. Dr. Handel lives in Denver, Colorado.
Ed Hsiao, MD/PHD received his doctorate from Johns Hopkins, did his internal medicine residency at Johns Hopkins Hospital, and went to the University of California at San Francisco for his endocrine fellowship. Ed’s research is driven by a bedside-to-bench-to-bedside approach, using clinical observations and patient samples to inspire research with the long term goal of improving the care of patients with all types of skeletal disorders. His laboratory uses a combination of human stem cell and mouse models to study how genetics and hormone signaling contributes to the normal formation of key skeletal tissues such as bone, cartilage, muscle, and fat. The lab also uses human induced pluripotent stem cells and genomics to understand what happens to the genetic and hormone signals that results in diseases affecting the musculoskeletal system. He sees patients with metabolic and rare bone diseases, including fibrous dysplasia and McCune Albright syndrome, in the Metabolic Bone Clinic at the University of California, San Francisco.
Janice Lee, MD is an oral and maxillofacial surgeon who treats children and adults. Her areas of expertise include facial reconstruction, maxillofacial pathology and craniofacial anomalies. Previously a member of the Craniofacial Anomalies team at UCSF Medical Center in San Francisco, CA, she currently practices at the National Institutes of Health in Bethesda, MD. Her research is in the area of bone marrow stem cells and the effects of age on their ability to differentiate and form bone. During her previous training at the National Institutes of Health, she was the maxillofacial specialist for a team evaluating and treating one of the largest populations of patients with McCune-Albright syndrome and polyostotic fibrous dysplasia.
Lynn M. Lindaman MD, specializes in pediatric orthopaedics, sports medicine & general orthopaedics in Des Moines, Iowa. He is also an individual with fibrous dysplasia.
Frederick Singer, MD lives in southern California. He is Director of the Endocrine/Bone Disease Program at the John Wayne Cancer Institute in Santa Monica, CA and is clinical professor of medicine at the Geffen School of Medicine at UCLA. He is a past chairman of the Board of Directors of The Paget Foundation and a past president of the American Society for Bone and Mineral Research. He has a long term interest in disorders of the skeleton.
Scientific Advisory Council
The Fibrous Dysplasia Foundation Scientific Advisory Council (SAC) is made up of medical clinicians and researchers with knowledge of skeletal disease and good scientific practice in the investigation of complex multi-system / endocrine related rare disease. Members will assist the Board of Directors in
- Setting the parameters for a patient registry/bio-repository and establishing best ethical practices in the handling of patient data.
- Advising the foundation on future directions for research and participate in the creation of requests for proposals.
- Evaluating proposals submitted to the FD Foundation for research grants
Should a SAC member become involved in FD, MAS or Cherubism research and wish to apply for FD Foundation research funds or develop any other conflict of interest with the SAC mission to evaluate proposals, it is expected that she or he will resign.
Rare Disease Therapeutic Development
Andrew Shenker, MD, PhD (Chair)
Independent Consultant in Rare Diseases and Gene Therapy
Bone and Mineral Metabolism, Genetics
Michael Whyte, MD
Professor of Medicine, Pediatrics, and Genetics
Washington School of Medicine
Medical-Scientific Director, Center for Metabolic Bone Disease and Molecular Research,
Shriner’s Hospitals for Children,
St. Louis, MO
Leonard Kaban, DMD, MD
Walter C. Guralnick Distinguished Professor
Department of Oral and Maxillofacial Surgery
Massachusetts General Hospital
Harvard School of Dental Medicine
Henry Kronenberg, MD, PhD
Chief, Endocrine Unit
Massachusetts General Hospital
Professor of Medicine
Harvard Medical School
Dolores Shoback, MD
Professor in Residence
University of California at San Francisco School of Medicine
Department of Medicine
Division of Endocrinology
Horacio Plotkin, MD
Head of Clinical Development, Rare Diseases
Bone and Mineral Metabolism
Harald Werner Jueppner
Massachusetts General Hospital
Endocrine Unit, Thier 10
55 Fruit St
Boston, MA 02114
Yale Pediatric Endocrinology
2 Church Street South
New Haven, CT 06519
Frank Barry, PhD
Director, National Centre for Biomedical Engineering Science Professor of Cellular Therapy
Regenerative Medicine Institute
National University of Ireland
Rare disease registry
Cornelius Boerkoel, MD, PhD
Undiagnosed Diseases Program, NHGRI, NIH
9 Memorial Drive, Building 9 Room 1E100
Bethesda, MD 20892
Rare disease biorepository
Dr Susanne Ragg MD PhD
Director, Center for Computational Diagnostics
702 Barnhill Dr. ROC 4340
Indianapolis, IN 46202